The enhancement of social functioning as a therapeutic principle in the management of depression

Journal of Psychopharmacology

Volumn 11, Issue 4 SUPPL., 1997, Pages

  Healy, David ^a,b   McMonagle, Thomas ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

^b Hergest Unit   (United Kingdom)

Author keywords

Depression; Psychiatric status rating scales; Psychological adaptation; Reboxetine; Self assessment; Social functioning

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

CONFERENCE PAPER; DEPRESSION; HUMAN; PRIORITY JOURNAL; RATING SCALE; SELF EVALUATION; SOCIAL INTERACTION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; SOCIAL BEHAVIOR;

EID: 0030779414     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Adeniran R, Healy D, Sharp H M, Williams J M G, Minors D S, Waterhouse J M (1996) Interpersonal sensitivity predicts depressive symptom response to the circadian rhythms disruption of night work. Psych Med 26: 1211-12 21
2. Bech P (1989) Clinical effects of selective serotonin reuptake inhibitors. In Dahl SO, Gram LF (eds), Clinical pharmacology in psychiatry. Springer-Verlag, Berlin 7: 81-93
3. Berzewski H, Van Moffaert M, Gagiano C A (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 7 (Suppl. 1): S37-S47
4. Bosc M, Dubini A, Polin V (1997) Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 7 (Suppl. 1): S57-S70
5. Brunner H G, Nelen M, Breakefield X O, Ropers H H, van Oost B A (1993) Abnormal behaviour associated with a point mutation in the structural gene for monoamine oxidase A. Science 262: 578-580
6. Carlsson A (1982) Rationale and design of a selective inhibitor of 5-HT re-uptake. Br J Clin Pract 19 (Suppl.): 19-21
7. Carlsson A, Corrodi H, Fuxe K, Hökfelt T (1969) Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-metatyramine. Eur J Pharmacol 5: 357-366
8. Claridge G, Healy D (1994) The psychopharmacology of individual differences. Hum Psychopharmacol 9: 285-298
9. Cloninger C R (1986) A unified biosocial theory of personality and its role in the development of anxiety states. Psych Dev 3: 167-226
10. Dubini A, Bosc M, Polin V (1997a) Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 7 (Suppl. 1): S49-S55
11. Dubini A, Bosc M, Polin V (1997b) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 11(Suppl.): S17-S23
12. Elkin I, Shea T, Watkins J T, Imber S D, Sotsky S M, Collins J F, Glass D R, Pilkonis PA, Leber W R, Docherty J P, Fiester S J, Parloff M B (1989) National Institute of Mental Health treatment of depression collaborative program: general effectiveness of treatments. Arch Gen Psychiatr 46: 971-986
13. Fitzgerald K, Healy D (1995) Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Hum Psychopharmacol 10: 215-220
14. Frank E, Kupfer D J, Perel J M, Comes C, Jarrett D B, Masllinger A G, Thase M E, McEachran A B, Grochocinski V J (1990) Three year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatr 47: 1093-1099
15. Gray J A (1982) The neuropsychology of anxiety. Oxford University Press, Oxford
16. Hamilton M (1960) A rating scale for depression. J Neuro Neurosurg Psych 23: 56-62
17. Healy D (1987) The structure of psychopharmacological revolutions. Psych Dev 5: 349-376
18. Healy D (1997) The antidepressant era. Harvard University Press, Boston
19. Healy D, Waterhouse J M (1991) Reactive rhythms and endogenous clocks: a shift work model of affective disorders. Psych Med 21: 557-564
20. Healy D, Minors D S, Waterhouse J M (1993) Shiftwork, helplessness and depression. J Affect Dis 29: 17-25
21. Hooley J M, Orley J, Teasdale J D (1986) Levels of expressed emotion and relapse in depressed patients. Br J Psychiatr 148: 642-647
22. Jachuk S J, Brierley H, Jachuk S, Willcox P M (1982) The effect of hypotensive drugs on the quality of life. J Roy Coll Gen Pract 32: 103-105
23. Kagan J (1994) Galen's prophecy. The role of temperament. Basic Books, New York
24. Kielholz P (1968) Die Behandlung endogener Depressionem mit Psychopharmaka. Deutsch Med Wochenschrft 93: 701-710
25. Klerman G L, DiMascio A, Weissman M M, Prusoff B, Paykel E S (1974) Treatment of depression by drugs and psychotherapy. Am J Psychiatr 131: 186-191
26. Kline N S (1959) Scales and checklists. In Cole J O, Gerard R W (eds), Psychopharmacology: problems in evaluation. National Academy of Sciences/National Research Council, Washington DC, pp. 485
27. Kramer P (1993). Listening to Prozac. Viking Penguin, New York
28. Lopez-Ibor J, Guelfi J, Pletan Y, Tournox A, Prost J F (1996) Milnacipram and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (Suppl. 4): 41-46
29. Montgomery S A (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 7 (Suppl. 1): 3-9
30. Montgomery S A, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psych 134: 382-389
31. Montgomery S A, James D, Montgomery D B (1987) Pharmacological specificity is not the same thing as clinical selectivity. J Psychopharmacol 3: 179-183
32. Parker G, Hadzi-Pavlovic D (1996) Melancholia. A disorder of movement and mood. Cambridge University Press, Cambridge
33. Potter W Z, Manji H K (1994) Clinical onset of antidepressant action: implications for new drug development. In Langer S Z, Brunello N, Racagni G, Mendlewicz J (eds), Critical issues in the treatment of affective disorders. Karger, Basel, pp. 118-126
34. Sapolsky R M (1990) Adrenocortical function, social rank and personality among wild baboons. Biol Psychiatr 28: 862-878
35. Sapolsky R M (1991) Testicular function, social rank and personality among wild baboons. Psychoneuroendocrinol 16:281-293
36. Sapolsky R M (1992) Cortisol concentrations and the social significance of rank instability among wild baboons. Psychoneuroendocrinol 17: 701-709
37. Sobin C, Sackheim H A (1997) Psychomotor symptoms of depression. Am J Psychiatr 154: 4-17
38. Sotsky S, Glass D R, Shea M T, Pilkonis P A, Collins J F, Elkin I, Watkins J T, Imber S D, Leber W R, Moyer J, Oliveri M E (1991) Patient predictors of response to psychotherapy and pharmacotherapy: findings of the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatr 148: 997-1008
39. van Praag H (1992) 'Make-believes' in psychiatry or the perils of progress. Brunner-Mazel, New York
40. Weissman M M (1997) Beyond symptoms: social functioning and new antidepressants. J Psychopharmacol 11(Suppl.): S5-S8
41. Weissman M M, Klerman G L, Paykel E S, Prusoff B A, Hanson B (1974) Treatment effects on the social adjustment of depressed patients. Arch Gen Psych 30: 771-778
42. Weissman M M, Prusoff B, DiMascio A, Neu C, Goklaney, Klerman G L, (1979) The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychother 136: 555-558
43. Wheatley D, Kremer C (1997) A randomized double-blind comparison of mirtazapine and fluoxetine in patients with major depression. American Psychiatric Association, Annual Meeting, San Diego, May 1997 Abstract NR208
44. Zung WHK (1965) A self-rating depression scale. Arch Gene Psych 12: 53-70